Terrence A Duffy

Terrence A Duffy sells 35,000 CME shares for $10,447,865.76; holds 55,630 post-transaction

Terrence A Duffy, Chairman and CEO of CME Group, executed 2 separate sales totaling 35,000 shares for $10,447,865.76 on 2026-05-15 at blended average price $298.51. This sale reduced his holdings by 38.6% to 55,630 shares remaining. The transaction occurred at prices materially below the current price of $305.12 and well below the 52-week high of $329.16. Across his cross-ticker track record, Duffy's 7 prior sells averaged a 90-day return of +2.4%, indicating his prior sales have generally preceded stock appreciation; at CME specifically, 2 of 5 prior sales posted negative 90-day returns. The stock is trading at a P/E of 4.94 on $1.9B quarterly revenue and $1.2B net income, with annual revenue growth of 6.4%.

CME CEO Terrence A. Duffy sold 25.0K shares for $6.7M on 2025-12-11; holds 65.8K shares remaining (-27.5%)

Terrence A. Duffy, CME's Chairman and CEO, executed two separate sales on 2025-12-11 totaling 25,000 shares (25.0K shares) at blended average $269.55, reducing his holdings by 27.5% from 90.8K to 65.8K shares. The timing is notable: the stock currently trades at $272.18, up 4.8% over 90 days, and his prior four measurable same-ticker sales at CME showed a 75% well-timed rate (three of four resulted in negative 90-day returns, meaning he sold before declines). His cross-ticker track record also demonstrates a 75.00% well-timed rate across five prior sells with an average 90-day return of -2.6%. CME itself remains fundamentally sound with strong recent performance: $1.5B quarterly revenue (+9.9% YoY), $908.0M net income, and an attractive P/E of 5.08. The sale represents a material reduction in the CEO's stake at a price modestly below the 52-week high, warranting close observation of his stated rationale and any subsequent market moves.

CME CEO Duffy sells 30,000 shares ($7.8M) at $259.18; holds 53,205 shares post-sale with strong 75% well-timed sell record

Terrence A Duffy, Chairman and CEO of CME Group Inc., sold 30,000 shares at $259.18 on 2025-03-11 for $7,775,400.00, reducing his holdings by 36.1% to 53,205 shares. The sale occurred near the 52-week high of $262.28 (-0.7%), and the stock has advanced 6.4% over the prior 30 days and 11.2% over 90 days. His cross-ticker track record shows a 75.00% well-timed rate across 4 prior sells with an average 90-day return of -2.5%, and at CME specifically, 3 of 4 prior sales were followed by declines (including -4.3%, -4.6%, and -5.2% at 90 days). The timing pattern—selling near multi-month highs with a strong historical record of selling before declines—suggests this transaction may be another instance of Duffy executing trades when valuations are extended. CME's fundamentals remain robust with $1.6B quarterly revenue, $912.8M net income, and a low P/E of 4.87, so this sale does not appear to reflect operational deterioration but rather reflects the CEO's demonstrated pattern of deploying sales at elevated price levels.